![Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar | Nature Communications Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-35653-z/MediaObjects/41467_2022_35653_Fig1_HTML.png)
Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar | Nature Communications
Qatar: Eligible Indian travellers, vaccinated with both does of Covidhield, can skip quarantine | Times of India Travel
![Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study - The Lancet Infectious Diseases Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/7908e9d3-aeb1-4f73-a8b2-878a8428117d/gr1_lrg.jpg)
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study - The Lancet Infectious Diseases
![Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas](https://www.thelancet.com/cms/attachment/d17f8c7e-ef09-420d-8007-d11155f47788/gr1.jpg)
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas
![Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer - ScienceDirect Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2666379122003366-fx1.jpg)
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer - ScienceDirect
![Delhi: Registration begins, vaccine booster shot for elderly from tomorrow | Delhi News - Times of India Delhi: Registration begins, vaccine booster shot for elderly from tomorrow | Delhi News - Times of India](https://static.toiimg.com/thumb/imgsize-23456,msid-88785825,width-600,resizemode-4/88785825.jpg)
Delhi: Registration begins, vaccine booster shot for elderly from tomorrow | Delhi News - Times of India
![Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy](https://www.astctjournal.org/cms/attachment/042fdca8-3e1e-48f7-a9ea-363f84ff3554/gr1.jpg)
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
![وزارة الصحة العامة on X: "The full quarantine exemption criteria are as follows: • 14 days must have passed after receiving the second dose of the vaccine before returning into Qatar and وزارة الصحة العامة on X: "The full quarantine exemption criteria are as follows: • 14 days must have passed after receiving the second dose of the vaccine before returning into Qatar and](https://pbs.twimg.com/media/EwCx0_FWQAEDBD4.jpg:large)
وزارة الصحة العامة on X: "The full quarantine exemption criteria are as follows: • 14 days must have passed after receiving the second dose of the vaccine before returning into Qatar and
![Saudi Arabia Booster Dose Mandatory: Saudi Arabia makes booster shots mandatory for its citizens travelling abroad from February 9 | Times of India Travel Saudi Arabia Booster Dose Mandatory: Saudi Arabia makes booster shots mandatory for its citizens travelling abroad from February 9 | Times of India Travel](https://static.toiimg.com/thumb/89391691/booster.jpg?width=1200&height=900)
Saudi Arabia Booster Dose Mandatory: Saudi Arabia makes booster shots mandatory for its citizens travelling abroad from February 9 | Times of India Travel
وزارة الصحة العامة on X: "Ministry of Public Health announces new Ehteraz functionalities for home quarantine and COVID-19 vaccination status.#YourSafetyIsMySafety https://t.co/tjZt2ya0r9" / X
![Vaccines | Free Full-Text | Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar Vaccines | Free Full-Text | Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar](https://www.mdpi.com/vaccines/vaccines-11-01522/article_deploy/html/images/vaccines-11-01522-g002-550.jpg)
Vaccines | Free Full-Text | Pfizer-BioNTech mRNA Vaccine Protection among Children and Adolescents Aged 12–17 Years against COVID-19 Infection in Qatar
Hamad Medical Corporation - COVID-19 vaccination certificate now available on MyHealth Patient Portal All individuals who have received 2 doses of the COVID-19 vaccine will automatically have a vaccination certificate available for
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
![Vaccines | Free Full-Text | BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar Vaccines | Free Full-Text | BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar](https://www.mdpi.com/vaccines/vaccines-09-00981/article_deploy/html/images/vaccines-09-00981-g001-550.jpg)
Vaccines | Free Full-Text | BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar
![COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/372ade5e-5f14-48a9-b960-4b5767839337/gr1_lrg.jpg)